Valuation : Biotika

Market Cap 12.04M 13.97M 11.29M 10.3M 19.41M 1.34B 19.47M 134M 52.26M 674M 52.46M 51.32M 2.24B P/E 2024
-4.39x
P/E 2025 -5.89x
Enterprise Value 8.33M 9.66M 7.81M 7.13M 13.42M 923M 13.47M 92.61M 36.13M 466M 36.28M 35.49M 1.55B EV / Sales 2024
0.55x
EV / Sales 2025 0.18x
Free-Float
42.84%
Yield 2024 *
-
Yield 2025 -
1 day+1.18%
1 week+1.18%
Current month-14.00%
1 month-15.69%
3 months+62.26%
6 months+81.05%
Current year+72.00%
1 week 17.2
Extreme 17.2
17.2
1 month 17
Extreme 17
17.2
Current year 9
Extreme 9
23
1 year 7
Extreme 7
23
3 years 7
Extreme 7
25
5 years 7
Extreme 7
42
10 years 7
Extreme 7
50.02
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - -
Chief Investment Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%+1.18%+115.00%-21.82% 14.03M
+0.35%+0.84%+19.98%+73.55% 48.07B
-0.08%-3.41%+55.31%+125.50% 40.17B
+0.15%+7.52%+20.56%+89.26% 12.42B
+0.25%-1.01%-9.89%+17.70% 12.01B
+0.19%+0.19%+30.98%+150.00% 9.38B
+0.07%+0.30%+27.45%+46.12% 7.78B
+0.04%-0.99%+52.61%-10.90% 7.24B
+2.24%+7.81%+28.93%+240.12% 7.27B
-0.53%-6.81%-35.67%+17.62% 5.33B
Average +0.39%-0.25%+30.53%+72.71% 14.97B
Weighted average by Cap. +0.23%+0.24%+28.23%+89.68%

Financials

2024 2025
Net sales 17.24M 20.01M 16.16M 14.76M 27.8M 1.91B 27.88M 192M 74.82M 965M 75.11M 73.48M 3.2B 18.15M 21.07M 17.02M 15.54M 29.27M 2.01B 29.36M 202M 78.79M 1.02B 79.1M 77.37M 3.37B
Net income -2.39M -2.77M -2.24M -2.05M -3.85M -265M -3.87M -26.59M -10.37M -134M -10.41M -10.19M -444M -1.19M -1.38M -1.11M -1.02M -1.92M -132M -1.92M -13.23M -5.16M -66.57M -5.18M -5.07M -221M
Net Debt -1.07M -1.24M -999K -912K -1.72M -118M -1.72M -11.85M -4.62M -59.63M -4.64M -4.54M -198M -3.71M -4.31M -3.48M -3.18M -5.99M -412M -6.01M -41.32M -16.12M -208M -16.18M -15.83M -690M
Logo Biotika
Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.
Employees
165
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. 1BSL01AE Stock